Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CP-690,550

First Posted Date: 2010-08-19

Last Posted Date: 2010-09-14

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01185184

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C

First Posted Date: 2010-08-18

Last Posted Date: 2010-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01184092

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Treatment A
Drug: Treatment B

First Posted Date: 2010-08-18

Last Posted Date: 2010-10-13

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT01184001

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-05161704 or placebo

First Posted Date: 2010-08-18

Last Posted Date: 2019-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01183715

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: pegvisomant

First Posted Date: 2010-08-13

Last Posted Date: 2012-01-05

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT01181973

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G

First Posted Date: 2010-08-13

Last Posted Date: 2011-01-24

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT01181700

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Phase 4

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2010-08-11

Last Posted Date: 2019-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT01180049

Locations: 🇷🇴
Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie, Bucuresti, Romania
🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇺🇸
Mercy Research Institute, Miami, Florida, United States

and more 27 locations

Conversion to Embeda With Rescue Trial

Phase 4

Terminated

Conditions: Chronic Disease
Pain

Interventions: Drug: morphine sulfate and naltrexone hydrochloride (EMBEDA)

First Posted Date: 2010-08-11

Last Posted Date: 2012-10-11

Lead Sponsor: Pfizer

Target Recruit Count: 684

Registration Number: NCT01179191

Locations: 🇺🇸
Washington Center for Pain Management PLLC, Edmonds, Washington, United States
🇺🇸
Pacific Coast Pain Management Center, Laguna Hills, California, United States
🇺🇸
Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States

and more 156 locations

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Phase 4

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Aromasin (exemestane)

First Posted Date: 2010-08-06

Last Posted Date: 2021-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 564

Registration Number: NCT01176916

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department, Bengbu, Anhui, China
🇨🇳
Breast and thyroid surgery of the Central Hospital of WuHan, WuHan, Hubei, China
🇨🇳
Hunan Provincial People's Hospital, Changsha, Hunan, China

and more 50 locations

A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis

Phase 3

Terminated

Conditions: Candidemia

Interventions: Drug: Anidulafungin/Fluconazole

First Posted Date: 2010-08-05

Last Posted Date: 2015-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT01176058

Locations: 🇨🇳
Changhai Hospital, Hemotology Department, Shanghai, Shanghai, China
🇨🇳
The First Affiliated Hospital of Medical School of Zhejiang University/Department of Hematology, Hangzhou, Zhejiang, China
🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy